Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upDREYLING, M; GHIELMINI, M; MARCUS, R et al.Annals of oncology. 2014, Vol 25, issn 0923-7534, iii76-iii82, SUP3Article

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upEICHENAUER, D. A; ENGERT, A; ANDRE, M et al.Annals of oncology. 2014, Vol 25, issn 0923-7534, iii70-iii75, SUP3Article

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaLADETTO, M; ZALLIO, F; BONDESAN, P et al.Leukemia. 2001, Vol 15, Num 12, pp 1941-1949, issn 0887-6924Conference Paper

Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas : a critical reappraisal of molecular strategiesCORRADINI, P; LADETTO, M; PILERI, A et al.Leukemia. 1999, Vol 13, Num 11, pp 1691-1695, issn 0887-6924Conference Paper

High-dose sequential chemoradiotherapy in multiple myeloma : residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autograftingCORRADINI, P; VOENA, C; ASTOLFI, M et al.Blood. 1995, Vol 85, Num 6, pp 1596-1602, issn 0006-4971Article

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana LinfomiARCAINI, L; VALLISA, D; TUCCI, A et al.Annals of oncology. 2014, Vol 25, Num 7, pp 1404-1410, issn 0923-7534, 7 p.Article

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upDREYLING, M; GEISLER, C; HERMINE, O et al.Annals of oncology. 2014, Vol 25, issn 0923-7534, iii83-iii92, SUP3Article

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upWILLEMZE, R; HODAK, E; ZINZANI, P. L et al.Annals of oncology. 2013, Vol 24, issn 0923-7534, vi149-vi154, SUP6Article

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cellsLAMORTE, S; FERRERO, S; ASCHERO, S et al.Leukemia. 2012, Vol 26, Num 5, pp 1081-1090, issn 0887-6924, 10 p.Article

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibitionSANTO, L; VALLET, S; CALABRESE, E et al.Oncogene (Basingstoke). 2010, Vol 29, Num 16, pp 2325-2336, issn 0950-9232, 12 p.Article

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support : a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)TARELLA, C; ZANNI, M; STELLA, M et al.Leukemia. 2007, Vol 21, Num 8, pp 1802-1811, issn 0887-6924, 10 p.Article

Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patientsRICCA, I; ROCCI, A; CALVI, R et al.Leukemia. 2007, Vol 21, Num 4, pp 697-705, issn 0887-6924, 9 p.Article

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphomaDREYLING, M; THIEBLEMONT, C; PILERI, S et al.Annals of oncology. 2013, Vol 24, Num 4, pp 857-877, issn 0923-7534, 21 p.Article

Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISHMILAN, M; RINALDI, A; CAVALLI, F et al.Annals of oncology. 2013, Vol 24, Num 5, pp 1378-1384, issn 0923-7534, 7 p.Article

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upZUCCA, E; COPIE-BERGMAN, C; RICARDI, U et al.Annals of oncology. 2013, Vol 24, issn 0923-7534, vi144-vi148, SUP6Article

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere statusRUELLA, M; ROCCI, A; TARELLA, C et al.Bone marrow transplantation (Basingstoke). 2010, Vol 45, Num 3, pp 505-512, issn 0268-3369, 8 p.Article

Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemiaROSSI, D; LOBETTI BODONI, C; BERNOCCO, E et al.Leukemia. 2009, Vol 23, Num 6, pp 1062-1072, issn 0887-6924, 11 p.Article

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSFRICCA, I; COMPAGNO, M; CARLO-STELLA, C et al.Leukemia. 2005, Vol 19, Num 4, pp 644-651, issn 0887-6924, 8 p.Article

Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantationVOENA, C; MALNATI, M; MAJOLINO, I et al.Bone marrow transplantation (Basingstoke). 2003, Vol 32, Num 8, pp 791-793, issn 0268-3369, 3 p.Article

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients : high tolerability with reversible cardiotoxicityFARELIA, C; ZALLIO, F; GLANNI, A. M et al.Leukemia. 2001, Vol 15, Num 2, pp 256-263, issn 0887-6924Conference Paper

Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients : evidence for long-term clinical and molecular remissionsTARELLA, C; CORRADINI, P; PILERI, A et al.Leukemia. 1999, Vol 13, Num 9, pp 1456-1462, issn 0887-6924Article

Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autograftingCORRADINI, P; ASTOLFI, M; CHERASCO, C et al.Blood. 1997, Vol 89, Num 2, pp 724-731, issn 0006-4971Article

Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphomaCORRADINI, P; LADETTO, M; ASTOLFI, M et al.British journal of haematology. 1996, Vol 94, Num 2, pp 376-378, issn 0007-1048Article

Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasiasCORRADINI, P; INGHIRAMI, G; PILERI, A et al.Leukemia. 1994, Vol 8, Num 5, pp 758-767, issn 0887-6924Article